JPRN-jRCT2080222500已完成2 期
Phase 2, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 130age old（—）
- 性别
- All
入选标准
- •Locally advanced/metastatic NSCLC.
- •- Radiological documentation of disease progression:
- •following 1st line EGFR TKI treatment but who have not received further treatment OR following prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy. Patients who received prior EGFR TKI and platinum-based doublet chemotherapy may have also received additional lines of treatment. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
- •- Disease progression following 1st line EGFR TKI treatment or following prior EGFR TKI and platinum-containing doublet chemotherapy.
- •- Confirmation tumour harbours EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q). Patients must have central confirmation of tumour T790M mutation positive status from a biopsy sample taken after confirmation of disease progression on the most recent treatment regimen.
- •- WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks. min life expectancy of 12 weeks.
- •- At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as more than 10mm in the longest diameter (except lymph nodes which must have short axis more than 15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements.
- •- Females of child-bearing potential using contraception; negative pregnancy test.
- •18 Years and older, Japan patients aged at least 20 years
排除标准
- •- Treatment with an EGFR-TKI within 8 days of study entry; any cytotoxic chemotherapy, investigational agents or other anticancer drugs within 14 days of study entry; previous treatment with AZD9291 (or 3rd generation TKIs); major surgery within 4 weeks; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks; current treatment with potent inhibitors of CYP2C8 and potent inhibitors/inducers of CYP3A4.
- •- Unresolved toxicities from prior therapy.
- •- Unstable spinal cord compression/brain metastases.
- •- Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding diatheses or infection.
- •- Refractory nausea/vomiting, chronic gastrointestinal diseases or bowel resection.
- •- Cardiac disease.
- •- Past history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- •- Inadequate bone marrow reserve or organ function.
研究者
相似试验
尚未招募
不适用
QPiAML 2020 studyNL-OMON19921Prinses Máxima Centrum voor Kinderoncologie60
招募中
1 期
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML with normal NPM1.newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AMLCTIS2023-505000-27-01Prinses Maxima Centrum voor Kinderoncologie B.V.41
进行中（未招募）
1 期
A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly MDS patientsEUCTR2020-001165-36-ITDipartimento di Medicina Sperimentale e Clinica- Università di Firenze10
进行中（未招募）
1 期
Phase II Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients with MET Amplificatioeoplasm malignantMedDRA version: 18.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005696-93-DESanofi-aventis recherche & développement1
进行中（未招募）
1 期
Phase II Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients with MET AmplificatioEUCTR2014-005696-93-FRSanofi-aventis recherche & développement1